BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30486324)

  • 21. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
    Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
    BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China.
    Che YH; Chongsuvivatwong V; Li L; Sriplung H; Wang YY; You J; Ma SJ; Yan Y; Zhang RY; Shen T; Chen HM; Rao SF; Zhang XL
    Public Health; 2016 Jan; 130():13-20. PubMed ID: 25931438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
    Thein HH; Qiao Y; Zaheen A; Jembere N; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
    PLoS One; 2017; 12(10):e0185198. PubMed ID: 29016627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The burden of illness associated with hepatocellular carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Shah S; Thompson D
    J Hepatol; 2009 Jan; 50(1):89-99. PubMed ID: 18977551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Demographic and Clinicopathologic Factors of Patients With Hepatocellular Carcinoma in a Safety Net Hospital.
    Luu S; Hsu C; Silberfein EJ
    J Surg Res; 2020 Dec; 256():374-380. PubMed ID: 32739621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hospice offers more palliative care but costs less than usual care for terminal geriatric hepatocellular carcinoma patients: a nationwide study.
    Hwang SJ; Chang HT; Hwang IH; Wu CY; Yang WH; Li CP
    J Palliat Med; 2013 Jul; 16(7):780-5. PubMed ID: 23790184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival.
    Breunig IM; Shaya FT; Hanna N; Seal B; Chirikov VV; Daniel Mullins C
    Value Health; 2013; 16(5):760-8. PubMed ID: 23947969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    J Comp Eff Res; 2018 Mar; 7(3):209-221. PubMed ID: 29231047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.
    Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS
    J Comp Eff Res; 2013 Jul; 2(4):435-44. PubMed ID: 24236684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.
    Kuo MJ; Chen HH; Chen CL; Fann JC; Chen SL; Chiu SY; Lin YM; Liao CS; Chang HC; Lin YS; Yen AM
    World J Gastroenterol; 2016 Mar; 22(12):3460-70. PubMed ID: 27022228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health care costs associated with hepatocellular carcinoma: a population-based study.
    Thein HH; Isaranuwatchai W; Campitelli MA; Feld JJ; Yoshida E; Sherman M; Hoch JS; Peacock S; Krahn MD; Earle CC
    Hepatology; 2013 Oct; 58(4):1375-84. PubMed ID: 23300063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma.
    Fukuda H; Sato D; Moriwaki K; Ishida H
    PLoS One; 2020; 15(8):e0237316. PubMed ID: 32790706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005).
    Marinho RT; Giria J; Moura MC
    World J Gastroenterol; 2007 Mar; 13(10):1522-7. PubMed ID: 17461443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan.
    Hsu CS; Lang HC; Huang KY; Chao YC; Chen CL
    Hepatol Int; 2018 Nov; 12(6):531-543. PubMed ID: 30426396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From good to good deal: value-focused research.
    Duszak R
    J Vasc Interv Radiol; 2012 Mar; 23(3):315-6. PubMed ID: 22365290
    [No Abstract]   [Full Text] [Related]  

  • 37. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
    Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
    Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular Carcinoma: A Decade of Hospitalizations and Financial Burden in the United States.
    Jinjuvadia R; Salami A; Lenhart A; Jinjuvadia K; Liangpunsakul S; Salgia R
    Am J Med Sci; 2017 Oct; 354(4):362-369. PubMed ID: 29078840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies.
    Chen BB; Shih IL; Wu CH; Hsu C; Chen CH; Shih TT; Liu KL; Liang PC
    J Vasc Interv Radiol; 2014 Mar; 25(3):371-8. PubMed ID: 24468045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.